Oncology assay kit TruSight

bloodplasmaFFPE tissues

Enable CGP with a large pan-cancer panel covering all major variant classes plus gene signatures (TMB, MSI, and HRD) from FFPE tissue. Targets 523 genes to assess all DNA and RNA variant types (SNV, CNV, indels, fusions), plus MSI, TMB and homologous recombination deficiency (HRD)† Delivers accurate results with hybrid–capture chemistry and sophisticated bioinformatics Reduces hands-on time with optional automation kits and methods* Also available in a high-throughput configuration Thorough results Evaluate > 500 pan-cancer biomarkers aligned with guidelines and clinical trials to increase chances of finding a positive biomarker with a single assay. Assess genomic instability with the optional add-on HRD kit.† Streamlined workflow Get results in 4–5 days using manual or automated workflows integrated with ready-to-use DRAGEN secondary analysis pipelines via on-premises server or in the cloud with Illumina Connected Analytics. Access insights and report generation with multiple options, including Illumina Connected Insights‡ or Pierian. Enable CGP with a comprehensive portfolio Identify disease-relevant biomarkers for clinical research with the TruSight Oncology 500 product line. TruSight Oncology 500 Assess relevant DNA and RNA cancer biomarkers from FFPE tumor tissue, now including HRD through an accessory kit to assess the Genomic Instability Score (GIS).† TruSight Oncology 500 High-Throughput Batch up to 192 samples at a time while using the same panel content and tissue input type as TruSight Oncology 500. TruSight Oncology 500 ctDNA Analyze circulating tumor DNA (ctDNA) in blood plasma via liquid biopsy with similar DNA panel con